NEW IN THE THERAPY OF ALZHEIMER'S DISEASE: ADUCANUMAB
Gromova D.O.
For quotation:
Gromova D.O. New in the treatment of Alzheimer's disease // Behavioral neurology. 2021. No. 2. pp. 48–55.
DOI 10.46393/2712-9675_2021_2_48_55
Annotation:
Alzheimer's disease (AD) is the most common pathology that causes dementia, requiring enormous financial costs to organize care for patients with this diagnosis. Despite the fact that the disease has been known since the first patient was described by Alois Alzheimer in 1906, the search for an effective pathogenetic treatment for this disease is still ongoing. The article presents modern approaches to the early diagnosis of AD at the prodromal predementia stage (stage of mild cognitive impairment associated with AD) and stage
mild dementia, as well as modern methods for assessing amyloid levels in the brain. Recommendations for the appropriate use of aducanumab (the first anti-amyloid drug approved by the FDA under an accelerated protocol) in real clinical practice, prepared by an expert panel led by J. Cummings, are discussed in detail: the clinical characteristics of the patient for whom treatment with aducanumab may be recommended, the drug titration schedule and its dose-dependent effect, possible side effects, including
ARIA (amyloid-related imaging abnormalities - amyloid-related pathological changes in imaging studies), assessment of the effectiveness and safety of therapy.
Journal "Behavioral Neuroscience" No. 2_2021
https://drive.google.com/file/d/1uCJ-UMtOZ4iweRqOvv7R3hE1ichAAmY6/view
Gromova D.O.
For quotation:
Gromova D.O. New in the treatment of Alzheimer's disease // Behavioral neurology. 2021. No. 2. pp. 48–55.
DOI 10.46393/2712-9675_2021_2_48_55
Annotation:
Alzheimer's disease (AD) is the most common pathology that causes dementia, requiring enormous financial costs to organize care for patients with this diagnosis. Despite the fact that the disease has been known since the first patient was described by Alois Alzheimer in 1906, the search for an effective pathogenetic treatment for this disease is still ongoing. The article presents modern approaches to the early diagnosis of AD at the prodromal predementia stage (stage of mild cognitive impairment associated with AD) and stage
mild dementia, as well as modern methods for assessing amyloid levels in the brain. Recommendations for the appropriate use of aducanumab (the first anti-amyloid drug approved by the FDA under an accelerated protocol) in real clinical practice, prepared by an expert panel led by J. Cummings, are discussed in detail: the clinical characteristics of the patient for whom treatment with aducanumab may be recommended, the drug titration schedule and its dose-dependent effect, possible side effects, including
ARIA (amyloid-related imaging abnormalities - amyloid-related pathological changes in imaging studies), assessment of the effectiveness and safety of therapy.
Journal "Behavioral Neuroscience" No. 2_2021
https://drive.google.com/file/d/1uCJ-UMtOZ4iweRqOvv7R3hE1ichAAmY6/view
